<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989868</url>
  </required_header>
  <id_info>
    <org_study_id>TNALD</org_study_id>
    <nct_id>NCT04989868</nct_id>
  </id_info>
  <brief_title>Effect of Trans-Nasal Afferent Loop Decompression on Post-Pancreaticoduodenectomy Pancreatic Fistula</brief_title>
  <official_title>Effect of Trans-Nasal Afferent Loop Decompression on Post-Pancreaticoduodenectomy Pancreatic Fistula: An Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pancreatic fistula (POPF) is a major complication and an important cause of&#xD;
      mortality after pancreaticoduodenectomy (PD). Trans-nasal afferent loop decompression&#xD;
      technique (TNALD) may reduce the rate of POPF based on our previous retrospective study. The&#xD;
      aim of this open-label randomized controlled trial is to determine whether TNALD is a&#xD;
      protective factor against the development of POPF after PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our previous retrospective study, decompression of the afferent jejunal and pancreatic and&#xD;
      biliary anastomoses with a special nasogastric tube and postoperative continuous closed&#xD;
      negative pressure suction was shown to be associated with a reduction in overall POPF rate&#xD;
      from 39% to 27% after PD. However, TNALD has the potential theoretical risk of increased&#xD;
      morbidity including pulmonary complications and delayed gastric emptying.&#xD;
&#xD;
      The objective of this prospective randomized study is to evaluate the impact of trans-nasal&#xD;
      afferent loop decompression on the incidence of complications after PD, especially POPF rate&#xD;
      according to International Study Group of Pancreatic Surgery (ISGPS) 2016 updates. We&#xD;
      hypothesize that the TNALD may prevent the development of POPF after PD. This study&#xD;
      randomizes patients to TNALD versus no TNALD group. Subgroup analysis of the outcomes in&#xD;
      different POPF risk groups is also planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pancreatic fistula (grade B+C)</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>Definition of postoperative pancreatic fistula was according ISGPS 2016 updates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pancreatic fistula related complications</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>Including intra-abdominal infection and intra-abdominal fluid accumulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative new-onset pulmonary complication</measure>
    <time_frame>up to 14 days after surgery</time_frame>
    <description>Including atelectasis, pleural effusion, pneumonitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other complications</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>Including postoperative hemorrhage, delayed gastric emptying, chyle leak, bile leak, sepsis, incision complication, deep vein thrombosis, pulmonary embolism, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complication and severe complication</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>Overall complication (Clavien-Dindo ≥ grade I) and severe complication (Clavien-Dindo ≥ grade III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention treatment</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>Number of patients with reintervention treatment for complications including percutaneous drainage, endoscopic procedure, angiographic procedure and reoperation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>Death for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of postoperative stay</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>From surgery to discharge including ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>New admission within 90-days of discharge from hospital for any reason</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">484</enrollment>
  <condition>Pancreatic Fistula</condition>
  <condition>Pancreaticoduodenectomy</condition>
  <condition>Complication of Surgical Procedure</condition>
  <arm_group>
    <arm_group_label>Trans-Nasal Afferent Loop Decompression Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Trans-Nasal Afferent Loop Decompression Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will NOT receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans-Nasal Afferent Loop Decompression</intervention_name>
    <description>A 14Fr silicon tube with multiple side holes within the range of 15 cm from the tip will be placed into the afferent jejunal limb with its end close to the pancreaticojejunostomy (&lt;3 cm) during the surgery. Continuous closed negative-pressure suction will be applied to that tube for 72 hours and after that the nasogastric tube will be removed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.</description>
    <arm_group_label>Trans-Nasal Afferent Loop Decompression Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Without Trans-Nasal Afferent Loop Decompression</intervention_name>
    <description>No decompression tube will be placed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.</description>
    <arm_group_label>No Trans-Nasal Afferent Loop Decompression Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient scheduled for elective open pancreaticoduodenectomy with Child reconstruction&#xD;
&#xD;
          -  Age &gt; 18 years and ≤ 85 years&#xD;
&#xD;
          -  Full agreement to participate and written informed consent is given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergent pancreaticoduodenectomy&#xD;
&#xD;
          -  Laparoscopic pancreaticoduodenectomy or robotic pancreaticoduodenectomy, including&#xD;
             transition to open approach&#xD;
&#xD;
          -  Participant in other trials of pancreaticoduodenectomy with interfering interventions&#xD;
             and/or endpoints&#xD;
&#xD;
          -  Patient with severe co-morbidity(s) before surgery, including severe insufficiency in&#xD;
             kidney, heart and/or liver, etc.&#xD;
&#xD;
          -  Patient had medication history of corticosteroids over 3 days during last 30 days&#xD;
             before surgery&#xD;
&#xD;
          -  No need for pancreaticojejunostomy during pancreaticoduodenectomy (i.e. past left&#xD;
             pancreatectomy, pancreaticogastrostomy, etc.), or pancreatic anastomosis cannot be&#xD;
             reconstructed for any reason&#xD;
&#xD;
          -  External stenting is used during the surgery for any reason&#xD;
&#xD;
          -  Nasogastric tube is inserted and kept for postoperative gastric decompression&#xD;
&#xD;
          -  In any situation that the placement of afferent loop decompression tube is medically&#xD;
             inappropriate or not infeasible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang K Rong, MD</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang K Rong, MD</last_name>
    <phone>+8615312995688</phone>
    <email>jiangkuirong@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lu Z Peng, MD</last_name>
    <phone>+8613813946958</phone>
    <email>surgeonmark@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang K rong</last_name>
      <phone>+86-153-1299-5688</phone>
      <email>jiangkuirong@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Kuirong Jiang</investigator_full_name>
    <investigator_title>Director of Pancreas Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

